Home / Oncology

Oncology

Vargatef Plus Docetaxel Could be an Option After Failure of Immunotherapy in Lung Cancer

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study …

Read More »

Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer

GENEVA, Dec. 14, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA (prostate stem …

Read More »

Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) — Guardant Health (Nasdaq: GH) announced a multi-year agreement with AstraZeneca (NYSE: AZN) to develop blood-based companion diagnostic (CDx) tests supporting the commercialization of AstraZeneca’s oncology portfolio based on Guardant’s industry-leading comprehensive liquid biopsy platform. Under the terms of the agreement, Guardant …

Read More »

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug Candidates

WALTHAM, Mass., Dec. 13, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed two TriNKET™ immunotherapy drug candidates to Celgene Corporation and its affiliates (“Celgene”) for $12m each plus prospective milestones and royalties.  The licenses represent the first two of four hematological cancer targets …

Read More »

OncoSec Reports Updated Tumor Responses in Phase 2b Study of Tavo in Combination with Keytruda in Refractory Metastatic Melanoma

SAN DIEGO and PENNINGTON, N.J, Dec. 12, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies, today announced an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™ (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® …

Read More »

Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies

NASHVILLE, Tenn. and TOKYO and MUNICH and BASKING RIDGE, N.J., Dec. 10, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute announced today a strategic oncology development collaboration. This partnership brings together Daiichi Sankyo’s expertise in developing novel cancer agents with Sarah Cannon’s leadership …

Read More »

FDA Grants Orphan Drug Designation to Merck KGaA’s Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

DARMSTADT, Germany, December 10, 2018 /PRNewswire/ — FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer First regulatory designation for M7824 following recent presentation of first clinical data in BTC BTC is a group of rare, aggressive gastrointestinal cancers associated with limited treatment options and …

Read More »

Bristol-Myers Squibb and Vedanta Collaborate to Evaluate Opdivo and VE800 in Advanced or Metastatic Cancers

NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers. In a range of preclinical models of cancer, …

Read More »

Myriad Study Demonstrates EndoPredict Can Guide Chemotherapy Decision for Women with Early-Stage Breast Cancer

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas.  …

Read More »

AstraZeneca’s Phase 3 Head and Neck Cancer Trial with Imfinzi and Tremelimumab Fails to Meet Primary Endpoints

AstraZeneca and MedImmune, its global biologics research and development arm, today announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and …

Read More »